Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens

Transplantation

Volumn 56, Issue 6, 1993, Pages 1518-1523

  Abhyankar, Sunil ^a,b   Gilliland, D Gary ^b,c   Ferrara, James L M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN RECEPTOR; MINOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; IMMUNOREGULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SURVIVAL TIME; TRANSCRIPTION REGULATION;

ANIMAL; BASE SEQUENCE; BONE MARROW TRANSPLANTATION; CYTOKINES; DNA PRIMERS; FEMALE; GRAFT VS HOST DISEASE; INTERLEUKIN-1; INTERLEUKIN-2; MICE; MICE, INBRED CBA; MINOR HISTOCOMPATIBILITY ANTIGENS; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; SPLEEN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR;

EID: 0027716849     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199312000-00045     Document Type: Article

References (40)

1. Dunn CJ. Cytokines as mediators of chronic inflammatory disease. In: Kimball ES, ed. Cytokines and inflammation. Boca Raton, FL: CRC Press, 1991:1.
2. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328:106.
3. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1985; 234: 470.
4. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF mono clonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662.
5. Ferrara JLM, Deeg HJ. Graft versus host disease. N Engl J Med 1991; 324: 667.
6. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-indentical siblings. N Engl J Med 1992; 327:1613.
7. Mc Carthy PL, Abhyankar S, Neben S, et al. Inhibition of interleu kin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991; 78:1915.
8. Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administra tion of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloen-graftment. J Exp Med 1990; 171: 645.
9. Piguet PF, Grau GE, Allet B, Vassalli PJ. Tumor necrosis factor/ cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 1987; 166:1280.
10. Nestel FP, Price K8, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405.
11. Komgold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T-cells from marrow. J Exp Med 1978; 148:1687.
12. Gilliland DG, Perrin S, Blanchard K, Bunn HF. Analysis of cyto kine mRNA and DNA: detection and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 2725.
13. Wang AM, Doyle MV, Mark DF. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 1989; 86: 9717.
14. Sakamoto H, Michaelson J, Golan DE, et al. Lymphocytes with a novel CD4+ CD8" CD3~ phenotype are effectors of experimental cutaneous graft-versus-host disease. Proc Natl Acad Sci USA 1991; 88: 10890.
15. Innis MA, Gelfand DH. Optimization of PCRs. In: Innis MA, Gelfand DH, Sininsky JJ, White TJ, eds. PCR protocols. San Diego: Academic Press, 1989: 3.
16. Murray LJ, Lee R, Martens C. In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-Ipr/Ipr mouse. Eur J Immunol 1990; 20: 163.
17. Sale GE, Lemer KG, Barker EA, Shulman HM, Thomas ED. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977; 89: 621.
18. Mc Intyre KW, Stepan GJ, Kolinsky KD, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173: 931.
19. Hakim FT, Sharrow SO, Payne S, Shearer GM. Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult Fi mice injected with parental lymphocytes. J Immunol 1991; 146: 2108.
20. Sprent J, Schaefer M, Lo D, Komgold R. Properties of purified T cell subsets: II. In vivo responses to class I vs. class II H-2 differences. J Exp Med 1986; 163: 998.
21. Ferrara JLM, Marion A, Mc Intyre JF, Murphy GF, Burakoff SJ. Amelioration of acute graft versus host disease due to minor histocompatibility antigens by in vivo administration of antiinterleukin 2 receptor antibody. J Immunol 1986; 137:1874.
22. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341.
23. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336.
24. Faherty DA, Claudy V, Plocinski JM, et al. Failure of IL-1 receptor antagonist and monoclonal anti-IL-1 receptor antibody to inhibit antigen-specific immune responses in vivo. J Immunol 1992; 148: 766.
25. Fanslow WC, Sims JE, Sassenfeld H, et al. Regulation of alloreac-tivity in vivo by a soluble form of the interleukin-1 receptor. Science 1990; 248: 739.
26. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962.
27. Hibbs JB Jr, Taintor RR, Vavrin Z. Macrophage cytoxocity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987; 235: 473.
28. Stuehr DJ, Nathan CF. Nitric oxide: a macrophage product re sponsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989; 169: 1543.
29. Nussler AK, Di Silvio M, Billiar TR, et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 1992; 176: 261.
30. Curran RD, Billiar TR, Stuehr DJ, et al. Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis. Ann Surg 1990; 212: 462.
31. Antin JH, Ferrara JLM. Cytokine dysrégulation and acute graft-versus-host disease. Blood 1992; 80: 2964.
32. Langrehr JM, Murase N, Markus PM, et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 1992; 90: 679.
33. Garside P, Hutton AK, Severn A, Liew FY, Mowat AM. Nitric oxide mediates intestinal pathology in graft-versus-host disease. Eur J Immunol 1992; 22: 2141.
34. Langrehr JM, Dull KE, Ochoa JB, et al. Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allo8pecific CTL. Transplantation 1992; 53: 632.
35. Ferrara JLM, Guillen PF, van Dijken PJ, Marion A, Murphy GF, Burakoff SJ. Evidence that large granular lymphocytes of donor origin mediate acute graft-versus-host disease. Transplantation 1989; 47: 50.
36. Ghayur T, Seemayer TA, Kongshawn PAL, Gartner JS, Lapp WS. Graft-versus-host (GVH) reactions in the beige mouse: an investigation of the role of host and honor natural killer cells in the pathogenesis of GVH disease. Transplantation 1987; 44: 261.
37. Miller JS, Verfaillie C, Mc Glave P. The generation of human natural killer cells from CD34+/DR" primitive progenitors in long-term bone marrow culture. Blood 1992; 80: 2182.
38. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81:1162.
39. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705.
40. Arend WP, Smith MF Jr, Janson RW, Joslin FG. IL-1 receptor antagonist and IL-1-beta production in human monocytes are regulated differently. J Immunol 1991; 147: 1530.